Affinity Asset Advisors LLC Acquires 250,000 Shares of Rezolute, Inc. (NASDAQ:RZLT)

Affinity Asset Advisors LLC lifted its holdings in shares of Rezolute, Inc. (NASDAQ:RZLT) by 15.6% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,850,000 shares of the company’s stock after buying an additional 250,000 shares during the period. Affinity Asset Advisors LLC owned about 4.61% of Rezolute worth $7,955,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Rezolute in the first quarter valued at approximately $37,000. Jeppson Wealth Management LLC bought a new stake in Rezolute during the 2nd quarter worth $45,000. XTX Topco Ltd increased its holdings in Rezolute by 205.8% in the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares in the last quarter. Acadian Asset Management LLC bought a new position in Rezolute in the first quarter valued at about $229,000. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of Rezolute by 366.0% during the second quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after purchasing an additional 42,597 shares in the last quarter. 82.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Craig Hallum assumed coverage on Rezolute in a research note on Tuesday, June 4th. They issued a “buy” rating and a $14.00 price objective for the company. JMP Securities restated a “market outperform” rating and issued a $7.00 price target on shares of Rezolute in a research report on Friday, September 20th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Monday, September 9th. Guggenheim began coverage on Rezolute in a report on Tuesday, August 27th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, BTIG Research lifted their target price on Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $11.57.

Rezolute Price Performance

Shares of NASDAQ RZLT opened at $4.69 on Wednesday. The company’s fifty day simple moving average is $4.62 and its 200 day simple moving average is $3.78. Rezolute, Inc. has a 12-month low of $0.72 and a 12-month high of $6.10.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). As a group, sell-side analysts forecast that Rezolute, Inc. will post -1.38 EPS for the current fiscal year.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.